<PAGE>

                       SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549

                                    FORM 10-Q

 /x/ QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE
     SECURITIES EXCHANGE ACT OF 1934

For Quarter Ended March 31, 2001
                                       OR

/ / TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
     SECURITIES EXCHANGE ACT OF 1934

For the transition period from                     to
                               -------------------    -------------------


                          Commission File Number 0-6516

                                 DATASCOPE CORP.
--------------------------------------------------------------------------------
             (Exact name of registrant as specified in its charter)

Delaware                                                    13-2529596
--------------------------------------------------------------------------------
(State of other jurisdiction of                             (I.R.S. Employer
incorporation or organization)                              Identification No.)

                      14 Philips Parkway, Montvale, New Jersey  07645-9998
--------------------------------------------------------------------------------
                            (Address of principal executive offices)

                                 (201) 391-8100
--------------------------------------------------------------------------------
                        (Registrant's telephone number, including area code)
         Former name, former address and former fiscal year, if changed since
         last report:

     Indicate by check mark whether the registrant
     (1) has filed all reports required to be filed by Section 13 or 15 (d) of
         the Securities Exchange Act of 1934 during the preceding 12 months (or
         for such shorter period that the registrant was required to file such
         reports), and
     (2) has been subject to such filing requirements for the past 90 days.
                YES    X           NO
                      ---             ---

Number of Shares of Company's Common Stock outstanding as of
April 30, 2001:    14,791,895.


<PAGE>



                        Datascope Corp. and Subsidiaries
                     Management's Discussion and Analysis of
                  Results of Operations and Financial Condition


Results of Operations

         Third quarter and first nine months of fiscal 2001 compared to the
         corresponding periods last year.

     Net Sales

         Net sales were $81.6 million in the third quarter and $224.9 million in
         the first nine months of fiscal 2001 representing an increase of 5% and
         4% compared to the third quarter and first nine months of fiscal 2000,
         respectively.

         Sales of the Cardiac Assist / Monitoring Products segment were $59.0
         million compared to $57.0 million in the third quarter and $164.1
         million in the first nine months of fiscal 2001 compared to $160.1
         million last year.

              Sales of Cardiac Assist products increased 2% in both the third
              quarter and first nine months of fiscal 2001 to $30.6 million and
              $86.3 million, respectively, reflecting increased sales of
              intra-aortic balloon pumps and flat sales of balloon catheters.
              Sales of intra-aortic balloon pumps increased as a result of
              strong customer demand for the System 98XT, Datascope's advanced
              performance balloon pump with automated timing control, which was
              launched last quarter.

              Patient Monitoring sales increased 5% to $28.4 million in the
              third quarter of fiscal 2001. The issue with supply of printed
              circuit boards for the Passport 2 monitor, which impacted
              shipments in the second quarter, was resolved in the third quarter
              as anticipated. Consequently, sales of the Passport 2 monitor
              posted solid growth and made its expected, major contribution to
              sales of patient monitoring products. Sales of the Accutorr(R)
              Plus blood pressure monitor and Masimo SpO2 sensors also
              contributed to growth in the third quarter. Sales of Patient
              Monitoring products increased 3% to $77.8 million in the first
              nine months of fiscal 2001.

         Sales of the Collagen Products / Vascular Grafts segment increased 9%
         to $22.3 million in the third quarter and 8% to $60.0 million in the
         first nine months of fiscal 2001.

              Sales of VasoSeal(R) arterial puncture sealing devices increased
              to $15.2 million, 1% above last year but 8% above the previous
              quarter as sales grew progressively stronger towards the latter
              part of the third quarter. During the quarter, Datascope completed
              a 30% expansion of its field sales organization, comprised of
              sales representatives and clinical specialists. The company
              believes that recent sales momentum has begun to reflect this
              expansion.


<PAGE>



              The company is encouraged by these results and plans to further
              increase the U.S. field organization over the next four months.
              For the first nine months of fiscal 2001 VasoSeal sales increased
              5% to $42.4 million.

              InterVascular sales increased 24% to $6.7 million in the third
              quarter, reflecting continued international demand for InterGard
              Silver(TM), the world's first anti- microbial vascular graft, and
              a favorable comparison to the depressed third quarter last year
              when the company's U.S. distributor reduced inventory. In fiscal
              2001, sales to that distributor have increased for the third
              consecutive quarter. InterVascular sales increased 13% to $16.9
              million in the first nine months of fiscal 2001.

         The stronger U.S. dollar compared to major European currencies
         decreased total sales by approximately $0.9 million in the third
         quarter and $3.7 million in the first nine months of fiscal 2001.

     Gross Profit (Net Sales Less Cost of Sales)

         The gross profit percentage was 61.0% for the third quarter and 60.7%
         for the first nine months of fiscal 2001, compared to 61.2% and 61.4%
         for the corresponding periods last year. The gross profit percentage in
         the third quarter and first nine months of fiscal 2001 was impacted
         primarily by lower average selling prices for patient monitoring
         products, incremental costs related to the circuit board supply issue
         and increased VasoSeal manufacturing expenses.

     Research and Development (R&D)

         R&D expenses, as a percentage of sales, were 8.0% for the third quarter
         and 8.4% for the first nine months of fiscal 2001, compared to 8.7% and
         8.9% for the corresponding periods last year.

         R&D expenses were $6.5 million in the third quarter and $18.8 million
         in the first nine months of fiscal 2001 compared to $6.7 million and
         $19.3 million for the corresponding periods last year. The reduced
         level of R&D expenses in the fiscal 2001 periods was primarily
         attributable to a more selective assessment of R&D projects and
         effective cost management in material procurement and selectively
         outsourcing projects and staffing more productively.

     Selling, General & Administrative Expenses (SG&A)

         SG&A expenses, as a percentage of sales, were 38.4% in the third
         quarter and 38.8% in the first nine months of fiscal 2001, compared to
         38.7% and 40.1% in the corresponding periods last year.

         SG&A expenses increased $1.3 million or 4% in the third quarter and
         $0.7 million or 1% in the first nine months of fiscal 2001 primarily as
         a result of higher selling and marketing expenses for Patient
         Monitoring products and the VasoSeal field organization expansion.


<PAGE>



         The stronger U.S. dollar compared to major European currencies
         decreased SG&A expenses by approximately $0.4 million in the third
         quarter and $2.3 million in the first nine months of fiscal 2001.

     Other Income and Expense

         Interest income in the third quarter of $0.8 million, was $0.1 million
         or 14% lower compared to the third quarter last year. The decline in
         interest income in the third quarter was the result of a $15.1 million
         lower average portfolio balance, partially offset by an increase in the
         average yield to 6.0% from 5.6%. Interest income was $2.8 million for
         the first nine months of fiscal 2001 compared to $2.7 million last
         year, due primarily to an increase in the average yield to 6.0% from
         5.5%.

         In the first quarter of fiscal 2001 we recorded a pretax gain of $593
         thousand, or $0.02 per share after tax, from the sale of an
         underutilized facility in Oakland, New Jersey.

     Income Taxes

         The consolidated effective tax rate was 31.2% for the third quarter and
         31.7% for the first nine months of fiscal 2001 compared to 32.0% and
         31.5% for the corresponding periods last year. The lower tax rate in
         the third quarter of fiscal 2001 was due mainly to the implementation
         of tax planning strategies to partially mitigate the impact from the
         expiration of a tax exemption for a manufacturing subsidiary in Europe
         in January 2000 and the higher effective tax rate on the special gain
         on sale of technology in the third quarter last year.

     Net Earnings

         Net earnings were $8.6 million or $0.56 per diluted share in the third
         quarter of fiscal 2001 compared to $10.5 million, or $0.66 per diluted
         share last year. Net earnings for the first nine months of fiscal 2001
         were $22.9 million or $1.48 per diluted share compared to $22.7 million
         or $1.42 per diluted share for the first nine months last year. Net
         earnings in the third quarter and first nine months of fiscal 2000
         included a special gain on sale of technology of $2.5 million after tax
         or $0.16 per diluted share.

         Excluding the special gain last year, net earnings were $8.6 million or
         $0.56 per diluted share in the third quarter and $22.9 million or $1.48
         per diluted share in the first nine months of fiscal 2001, compared to
         $8.0 million or $0.50 per diluted share and $20.2 million or $1.26 per
         diluted for the corresponding periods last year. The increased earnings
         in fiscal 2001 reflect:
             o    higher gross margin from increased sales
             o    greater expense control




<PAGE>



Liquidity and Capital Resources

     Working capital was $132.0 million at March 31, 2001, compared to $120.8
     million at June 30, 2000. The current ratio was 3.7:1 compared to 3.3:1.
     The increase in working capital and the current ratio was primarily the
     result of an increase in inventories ($11.3 million) and accounts
     receivable ($2.6 million).

     In the first nine months of fiscal 2001 cash provided by operations was
     $5.8 million, compared to $29.9 million last year. The decline is primarily
     attributable to an increase in inventories and accounts receivable and a
     reduction in accrued liabilities. Net cash provided by investing activities
     was $6.1 million, primarily attributable to maturities of marketable
     securities of $50.7 million, partially offset by $37.3 million purchases of
     marketable securities and the purchase of $8.4 million of property, plant
     and equipment. Net cash used in financing activities was $9.1 million,
     primarily due to stock repurchases of $8.1 million and $2.1 million
     dividends paid.

     During the first nine months of fiscal year 2001 we expended $8.1 million
     to purchase about 234 thousand shares of our common stock under the current
     $30 million stock repurchase program.

     We believe our financial resources are sufficient to meet our projected
     cash requirements.

     The moderate rate of current U.S. inflation has not significantly affected
     the company.

Euro Conversion

     As part of the European Economic and Monetary Union (EMU), a single
     currency (Euro) will replace the national currencies of most of the
     European countries in which we conduct our business. The conversion rates
     between the Euro and the participating nations' currencies have been fixed
     irrevocably as of January 1, 1999. During a transition period from January
     1, 1999 to December 31, 2001 parties may settle transactions using either
     Euro or the participating country's national currency. The participating
     national currencies will be removed from circulation between January 1,
     2002 and June 30, 2002 and replaced by Euro notes and coinage. Full
     conversion of all affected country operations to the Euro currency is
     expected to be completed by the time national currencies are removed from
     circulation.

     We are currently involved in the phased conversion to the Euro and the
     effects on revenues, costs and various business strategies are being
     assessed. We are able to conduct business in both the Euro and national
     currencies on an as needed basis, as required by the European Union. The
     cost of software and business process conversion is not expected to be
     material to our financial condition or results of operations.




<PAGE>



Information Concerning Forward Looking Statements

     This Management's Discussion and Analysis of Results of Operations and
     Financial Condition includes forward-looking statements that involve risks
     and uncertainties because of the possibility that market conditions may
     change, particularly as the result of competitive activity in the cardiac
     assist, arterial sealing and other markets served by the company, the
     company's ability to gain market acceptance for new products and the
     company's dependence on certain suppliers for patient monitoring, cardiac
     assist and VasoSeal products. Additional risks are the ability of the
     company to successfully introduce new products, continued demand for the
     company's products generally, the rapid and significant changes that
     characterize the medical device industry and the ability to continue to
     respond to such changes, the uncertain timing of regulatory approvals, as
     well as other risks detailed from time to time in documents filed by
     Datascope with the Securities and Exchange Commission.

Quantitative and Qualitative Disclosures About Market Risk

     Due to the global nature of our operations, we are subject to the exposures
     that arise from foreign exchange rate fluctuations. Our objective in
     managing the exposure to foreign currency fluctuations is to minimize net
     earnings volatility associated with foreign exchange rate changes. We enter
     into foreign currency forward exchange contracts to hedge a substantial
     portion of the foreign currency transactions which are primarily related to
     certain intercompany receivables denominated in foreign currencies. Our
     hedging activities do not subject us to exchange rate risk because gains
     and losses on these contracts offset losses and gains on the assets,
     liabilities and transactions being hedged.

     We do not use derivative financial instruments for trading purposes. None
     of our foreign currency forward exchange contracts are designated as
     economic hedges of our net investment in foreign subsidiaries.

     As of March 31, 2001, we had a notional amount of $6.5 million of foreign
     exchange forward contracts outstanding, all of which were in European
     currencies. The foreign exchange forward contracts generally have
     maturities that do not exceed 12 months and require us to exchange foreign
     currencies for U.S. dollars at maturity, at rates agreed to when the
     contract is signed.

<PAGE>
                        Datascope Corp. and Subsidiaries
                       Statements of Consolidated Earnings
                    (In thousands, except per share amounts)
                                   (Unaudited)

<TABLE>
<CAPTION>
                                               Nine Months Ended                       Three Months Ended
                                                    March 31,                               March 31,
                                        ------------------------------           -------------------------------
                                            2001                2000               2001                2000
                                        ----------           ---------           ---------           ----------

<S>                                      <C>                 <C>                 <C>                 <C>
Net Sales                                $ 224,900           $ 215,900           $  81,600           $  77,600
                                         ---------           ---------           ---------           ---------
Costs and Expenses:
  Cost of sales                             88,280              83,237              31,818              30,112
  Research and development
    expenses                                18,815              19,298               6,511               6,736
  Selling, general and
    administrative expenses                 87,276              86,601              31,338              30,008
  Gain on sale of technology                    --              (3,825)                 --              (3,825)
                                         ---------           ---------           ---------           ---------
                                           194,371             185,311              69,667              63,031
                                         ---------           ---------           ---------           ---------
Operating Earnings                          30,529              30,589              11,933              14,569
Other (Income) Expense:
  Interest income                           (2,800)             (2,661)               (812)               (939)
  Interest expense                              22                  15                  13                   5
  Other, net                                  (211)                110                 170                  60
                                         ---------           ---------           ---------           ---------
                                            (2,989)             (2,536)               (629)               (874)
                                         ---------           ---------           ---------           ---------
Earnings Before Taxes on Income             33,518              33,125              12,562              15,443
Taxes on Income                             10,628              10,429               3,922               4,948
                                         ---------           ---------           ---------           ---------
Net Earnings                             $  22,890           $  22,696           $   8,640           $  10,495
                                         =========           =========           =========           =========

Earnings Per Share, Basic                $    1.55           $    1.50           $    0.58           $    0.70
                                         =========           =========           =========           =========
Weighted Average Number of
  Common and Common Equivalent
  Shares Outstanding, Basic                 14,815              15,084              14,790              15,050
                                         =========           =========           =========           =========

Earnings Per Share, Diluted              $    1.48           $    1.42           $    0.56           $    0.66
                                         =========           =========           =========           =========
Weighted Average Number of
  Common and Common Equivalent
  Shares Outstanding, Diluted               15,463              16,022              15,405              15,989
                                         =========           =========           =========           =========
</TABLE>



                 See notes to consolidated financial statements
<PAGE>

                        Datascope Corp. and Subsidiaries
                           Consolidated Balance Sheets
                                 (In thousands)

<TABLE>
<CAPTION>
                                                                  March 31,               June 30,
                                                                    2001                   2000
                                                               ------------             -----------
Assets                                                          (unaudited)                 (a)
<S>                                                             <C>                      <C>
Current Assets:
  Cash and cash equivalents                                     $   5,286                $   2,102
  Short-term investments                                           41,876                   53,096
  Accounts receivable less allowance for
    doubtful accounts of $1,617 and $1,644                         71,650                   69,081
  Inventories                                                      50,277                   38,986
  Prepaid expenses and other current assets                        12,317                   10,014
                                                                ---------                ---------
      Total Current Assets                                        181,406                  173,279

Property, Plant and Equipment, net of accumulated
    depreciation of $53,736 and $58,234                            89,841                   86,243
Non-Current Marketable Securities                                  10,089                   12,235
Other Assets                                                       24,268                   23,034
                                                                ---------                ---------
                                                                $ 305,604                $ 294,791
                                                                =========                =========

Liabilities and Stockholders' Equity
Current Liabilities:
  Accounts payable                                              $  18,087                $  14,250
  Accrued expenses                                                 14,446                   11,165
  Accrued compensation                                             12,696                   19,662
  Deferred revenue                                                  4,175                    4,773
  Taxes on income                                                      --                    2,630
                                                                ---------                ---------
      Total Current Liabilities                                    49,404                   52,480

Other Liabilities                                                  14,742                   14,524
Stockholders' Equity
  Preferred stock, par value $1.00 per share:
    Authorized 5 million shares; Issued, none                          --                       --
  Common stock, par value $.01 per share:
    Authorized, 45 million shares; Issued and
    outstanding, 17,178 and 17,028 shares                             172                      170
  Additional paid-in capital                                       63,419                   60,646
  Treasury stock at cost, 2,383 and 2,149 shares                  (63,317)                 (55,247)
  Retained earnings                                               251,001                  230,187
  Accumulated other comprehensive loss                             (9,817)                  (7,969)
                                                                ---------                ---------
                                                                  241,458                  227,787
                                                                ---------                ---------
                                                                $ 305,604                $ 294,791
                                                                =========                =========

</TABLE>

                  (a) Derived from audited financial statements
                 See notes to consolidated financial statements

<PAGE>

                        Datascope Corp. and Subsidiaries
                      Statements of Consolidated Cash Flows
                             (Dollars in thousands)
                                   (Unaudited)

<TABLE>
<CAPTION>
                                                                             Nine Months Ended
                                                                                  March 31
                                                                     ---------------------------------
                                                                       2001                    2000
                                                                     ---------              ----------
<S>                                                                  <C>                     <C>
Operating Activities:

   Net cash provided by operating activities                         $  5,803                $ 29,940
                                                                     --------                --------

Investing Activities:
   Capital expenditures                                                (8,355)                (13,373)
   Proceeds from sale of Oakland facility                               1,112                      --
   Purchases of marketable securities                                 (37,290)                (66,970)
    Maturities of marketable securities                                50,656                  70,490
    AMG Equity Investment                                                  --                  (2,525)
                                                                     --------                --------
   Net cash provided by (used in) investing activities                  6,123                 (12,378)
                                                                     --------                --------

Financing Activities:
   Treasury shares acquired under repurchase programs                  (8,070)                (21,661)
   Exercise of stock options and other                                  1,079                   3,197
   Cash dividends paid                                                 (2,076)                 (1,204)
                                                                     --------                --------
   Net cash used in financing activities                               (9,067)                (19,668)
                                                                     --------                --------

   Effect of exchange rates on cash                                       325                     385
                                                                     --------                --------

Increase (decrease) in cash and cash equivalents                        3,184                  (1,721)
Cash and cash equivalents, beginning of period                          2,102                   4,572
                                                                     --------                --------

Cash and cash equivalents, end of period                             $  5,286                $  2,851
                                                                     ========                ========

Supplemental Cash Flow Information
   Cash Paid during the period for:
   Income taxes                                                      $ 11,589                $  7,803
                                                                     --------                --------

   Non-cash transactions:
   Net transfers of inventory to fixed assets
     for use as demonstration equipment                              $  5,868                $  5,794
                                                                     --------                --------
</TABLE>



                 See notes to consolidated financial statements

<PAGE>


                        Datascope Corp. and Subsidiaries
                   Notes to Consolidated Financial Statements
                 (Unaudited, in thousands except per share data)

1.  Basis of Presentation

The consolidated financial statements include the accounts of Datascope Corp.
and its subsidiaries (the "Company" - which may be referred to as "our", "us" or
"we").

The consolidated balance sheet as of March 31, 2001, the statements of
consolidated earnings for the three and nine month periods ended March 31, 2001
and 2000 and the statements of cash flows for the nine month periods ended March
31, 2001 and 2000 have been prepared by the Company, without audit. In our
opinion, all adjustments (which include only normal recurring adjustments) have
been made that are necessary to present fairly the financial position, results
of operations and cash flows for all periods presented.

Certain information and footnote disclosures normally included in financial
statements prepared in accordance with generally accepted accounting principles
have been condensed or omitted. We suggest that you read these condensed
consolidated financial statements in conjunction with the financial statements
and notes included in our Annual Report on Form 10-K for the fiscal year ended
June 30, 2000. The results of operations for the period ended March 31, 2001 are
not necessarily indicative of a full year's operations.

We have reclassified certain prior year information to conform with the current
year presentation.

2.  Inventories

Inventories are stated at the lower of cost or market, with cost determined on a
first-in, first-out basis.

                                    March 31,             June 30,
                                      2001                 2000
                                   ----------            ---------
      Materials                     $25,493               $17,462
      Work in Process                10,827                 7,888
      Finished Goods                 13,957                13,636
                                    -------               -------
                                    $50,277               $38,986
                                    =======               =======

3.  Stockholders' Equity

Changes in the components of stockholders' equity for the nine months ended
March 31, 2001 were as follows:

      Net earnings                                            $22,890
      Foreign currency translation adjustments                 (1,848)
      Common stock and additional paid-in
        capital effects of stock option activity                2,775
      Cash dividends on common stock                           (2,076)
        Purchases under stock repurchase plans                 (8,070)
                                                             ---------
        Total increase in stockholders' equity                $13,671
                                                             =========


<PAGE>

                        Datascope Corp. and Subsidiaries
                   Notes to Consolidated Financial Statements
                 (Unaudited, in thousands except per share data)

4.  Earnings Per Share

In accordance with Financial Accounting Standard No. 128, "Earnings Per Share",
we disclose both Basic and Diluted Earnings Per Share. The reconciliation of
Basic Earnings Per Share to Diluted Earnings Per Share is as follows:

<TABLE>
<CAPTION>
---------------------------------      --------------------------------------------------------------------------------------
For Three Months Ended                             March 31, 2001                             March 31, 2000
---------------------------------      --------------------------------------------------------------------------------------
                                            Net                     Per Share             Net                      Per Share
Basic EPS                                Earnings       Shares        Amount            Earnings       Shares        Amount
---------                              ------------  ------------  ------------       ------------  ------------  -----------

<S>                                    <C>           <C>           <C>                <C>           <C>           <C>
Earnings available to
   common shareholders                      $8,640        14,790         $0.58            $10,495        15,050        $0.70

Diluted EPS
Options issued to employees                     --           615         (0.02)                --           939        (0.04)
                                       ------------  ------------  ------------       ------------  ------------  -----------

Earnings available to
   common shareholders
   plus assumed conversions                 $8,640        15,405         $0.56            $10,495        15,989        $0.66
                                       ============  ============  ============       ============  ============  ===========

<CAPTION>
---------------------------------      --------------------------------------------------------------------------------------
For Nine Months Ended                              March 31, 2001                             March 31, 2000
---------------------------------      --------------------------------------------------------------------------------------
                                            Net                     Per Share             Net                      Per Share
Basic EPS                                Earnings       Shares        Amount            Earnings       Shares        Amount
---------                              ------------  ------------  ------------       ------------  ------------  -----------
<S>                                    <C>           <C>           <C>                <C>           <C>           <C>
Earnings available to
   common shareholders                     $22,890        14,815         $1.55            $22,696        15,084        $1.50

Diluted EPS
Options issued to employees                     --           648         (0.07)                --           938        (0.08)
                                       ------------  ------------  ------------       ------------  ------------  -----------

Earnings available to
   common shareholders
   plus assumed conversions                $22,890        15,463         $1.48            $22,696        16,022        $1.42
                                       ============  ============  ============       ============  ============  ===========
</TABLE>

5.  Comprehensive Income

In accordance with Financial Accounting Standard No. 130, "Reporting
Comprehensive Income", we disclose comprehensive income and its components. For
the three and nine month periods ended March 31, 2001 and 2000 our comprehensive
income was as follows:

<TABLE>
<CAPTION>
                                             Nine Months Ended         Three Months Ended
                                         -----------------------     -----------------------
                                           3/31/01      3/31/00       3/31/01       3/31/00
                                         ------------  ---------     ---------     ---------
<S>                                      <C>           <C>           <C>           <C>
   Net earnings                          $ 22,890      $ 22,696      $  8,640      $ 10,495
   Foreign currency translation loss       (1,848)       (1,390)       (1,484)         (974)
                                         --------      --------      --------      --------
   Total comprehensive income            $ 21,042      $ 21,306      $  7,156      $  9,521
                                         ========      ========      ========      ========
</TABLE>

<PAGE>

                        Datascope Corp. and Subsidiaries
                   Notes to Consolidated Financial Statements
                 (Unaudited, in thousands except per share data)

6.  Segment Information

Our business is the development, manufacture and sale of medical devices. We
have two reportable segments, Cardiac Assist / Monitoring Products and Collagen
Products / Vascular Grafts.

The Cardiac Assist / Monitoring Products segment includes electronic
intra-aortic balloon pumps and catheters that are used in the treatment of
vascular disease and electronic physiological monitors that provide for patient
safety and management of patient care.

The Collagen Products / Vascular Grafts segment includes extravascular
hemostasis devices which are used to seal arterial puncture wounds to stop
bleeding after cardiovascular catheterization procedures and a proprietary line
of knitted and woven vascular grafts and patches for reconstructive vascular and
cardiovascular surgery.

We have aggregated our product lines into two segments based on similar
manufacturing processes, distribution channels, regulatory environments and
customers. Management evaluates the revenue and profitability performance of
each of our product lines to make operating and strategic decisions. We have no
intersegment revenue. Net sales and operating earnings are shown below.

<TABLE>
<CAPTION>
                                                           Cardiac          Collagen
                                                           Assist/          Products/        Corporate
                                                          Monitoring        Vascular            and
                                                           Products          Grafts           Other (a)        Consolidated
-----------------------------------------------------   --------------    --------------   --------------    ----------------
Three months ended March 31, 2001
-----------------------------------------------------
<S>                                                     <C>               <C>              <C>               <C>
Net sales to external customers                               $59,021           $22,344             $235             $81,600
                                                        --------------    --------------   --------------    ----------------
Operating earnings                                             $6,425            $4,769             $739             $11,933
                                                        --------------    --------------   --------------    ----------------

-----------------------------------------------------
Three months ended March 31, 2000
-----------------------------------------------------
Net sales to external customers                               $56,976           $20,540              $84             $77,600
                                                        --------------    --------------   --------------    ----------------
Operating earnings                                             $7,661            $5,360          ($2,277)            $10,744
                                                        --------------    --------------   --------------    ----------------

-----------------------------------------------------
Nine months ended March 31, 2001
-----------------------------------------------------
Net sales to external customers                              $164,094           $60,007             $799            $224,900
                                                        --------------    --------------   --------------    ----------------
Operating earnings                                            $16,329           $11,888           $2,312             $30,529
                                                        --------------    --------------   --------------    ----------------

-----------------------------------------------------
Nine months ended March 31, 2000
-----------------------------------------------------
Net sales to external customers                              $160,137           $55,661             $102            $215,900
                                                        --------------    --------------   --------------    ----------------
Operating earnings                                            $18,803           $11,251          ($3,290)            $26,764
                                                        --------------    --------------   --------------    ----------------

<CAPTION>
-----------------------------------------------------------------------------------------------------------------------------
Reconciliation to consolidated earnings                          Nine Months Ended                   Three Months Ended
    before income taxes :                                   3/31/01           3/31/00          3/31/01             3/31/00
-----------------------------------------------------   --------------    --------------   --------------    ----------------
<S>                                                     <C>               <C>              <C>               <C>
Consolidated operating earnings                               $30,529           $26,764          $11,933             $10,744
Interest income, net                                            2,778             2,646              799                 934
Other (expense) income                                            211              (110)            (170)                (60)
Gain on sale of technology                                         --             3,825               --               3,825
                                                        --------------    --------------   --------------    ----------------
Consolidated earnings before taxes                            $33,518           $33,125          $12,562             $15,443
                                                        ==============    ==============   ==============    ================
</TABLE>

       (a) Net sales of life science products by Genisphere are included
       within Corporate and Other.

<PAGE>

                        Datascope Corp. and Subsidiaries
                   Notes to Consolidated Financial Statements
                 (Unaudited, in thousands except per share data)

7.  Restructuring Program

Based upon a review by senior management of all company operations, a
restructuring plan was approved in fiscal year 1999 to reduce the company's cost
structure and streamline certain operations. We recorded pretax restructuring
charges totaling $3.43 million, or $0.14 per share, during the second half of
fiscal 1999 related to the following cost reduction initiatives:

   o     Closure of InterVascular's Clearwater, Florida leased manufacturing
         facility in order to reduce costs and centralize operations in our
         expanded manufacturing facility in LaCiotat, France.

   o     Workforce reductions in certain administrative, R&D and manufacturing
         positions throughout the company.

   o     Writedown of certain Genisphere fixed assets based on the revised
         market entry strategy for the proprietary 3DNA technology. Under the
         revised market entry stategy we will focus product development on
         improving the performance of newly-developing technologies for drug
         discovery used by the pharmaceutical and biotech industries.

As of March 31, 2001, the remaining liability for the restructuring is $180
thousand for employee severance. No additional expenditures are expected to
complete the restructuring program.



<PAGE>



Part II:

    Item 6.   Exhibits and Reports on Form 8-K

              a.  Exhibits

                  none

              b.  Reports on Form 8-K.  No reports on Form 8-K have been filed
                   during the quarter for which this report is filed.



<PAGE>



                                                                       Form 10-Q






SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this Report to be signed on its behalf by the
undersigned, thereunto duly authorized.

                            DATASCOPE CORP.
                            Registrant







                            By: \s\   Lawrence Saper
                                ---------------------------------------
                                  Chairman of the Board and
                                  Chief Executive Officer






                            By: \s\   Leonard S. Goodman
                                -----------------------------------
                                  Vice President, CFO and Treasurer


Dated:  May 14, 2001